Modulation of mdr1 expression by cytokines in human colon carcinoma cells: An approach for reversal of multidrug resistance

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1384-1391

  Stein, U ^a,b   Walther, W ^a   Shoemaker, R H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Colon carcinoma cell; Cytokine; Multidrug resistance; Reversal

Indexed keywords

CYTOKINE; DOXORUBICIN; GAMMA INTERFERON; GLYCOPROTEIN P; INTERLEUKIN 2; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ARTICLE; CHEMOSENSITIVITY; COLON CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029828921     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.553     Document Type: Article

References (39)

1. ABRAHAM EH, PRAT AG, GERWECK L, SENEVERATNE T, ARCESI RJ, KRAMER R, GUIDOTTI G AND CANTIEELO HF. (1993). The multidrug resistance (mdr 1) gene product functions as an ATP channel. Proc. Natl Acaci. Sci. USA, 90, 312 - 316.
2. BORSELLINO N, CRESCIMANNO M, FLANDINA C, FLUGY A AND D'ALESSANDRO N. (1994). Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. Anticancer Res., 14, 2643 2648.
3. BRATTAIN MG, FINE WD, KHALHD FM, THOMPSON J AND BRATTAIN DE. (1981). Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res., 41, 1751 1756.
4. CHIN K-V, PASTAN I AND GOTTESMAN MM. (1993). Function and regulation of the human multidrug resistance gene. Adv. Cancer Res., 60, 157 180.
5. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 71 137.
6. EVANS CH AND BAKER PD. (1992). Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res., 52, 5893 - 5899.
7. FOGLER WE, PEARSON JW, VOLKER K, ARIYOSHI K, WATABE H, RIGGS CW, WILTROUT RH AND LONGO DL. (1995). Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J. Natl Cancer Inst., 87, 94 - 104.
8. GERMANN UA, PASTAN I AND GOTTESMAN MM. (1993). P-glycoproteins: mediators of multidrug resistance. Semin. Cell Biol., 4, 63 - 76.
9. GOLDSTEIN LJ, GALSKI H, FOJO A, WILLINGHAM M, LAI SL, GAZDAR A, PRIKER R, GREEN A, CRIST W, BRODEUR CM, LIEBER M, COSSMAN J, GOTTESMAN MM AND PASTAN I. (1989). Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst., 81, 116 - 124.
10. IWAHASHI T, OKOCHI E, ONO K, SUGAWARA I, TSURUO T AND MORI S. (1991). Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anticancer Res., 11, 1309 - 1312.
11. IZQUIERDO MA, SHOEMAKER RH, FLENS MJ, SCHEFFER GL, WU L, PRATHER TR AND SCHEPER RJ. (1996). Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer, 65, 230 - 237.
12. KAMIKASEDA K, STAVROU D AND FUKUI M. (1994). The enhanced antitumour activity of DNA topoisomerase 11-trapping drugs by natural human tumor necrosis factor against human glioma cell lines in vitro. Oncol. Reports, 1, 735-738.
13. KANG Y AND PERRY RR. (1994). Effect of α-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res., 54, 2952 - 2958.
14. KELLEN JA. (1993). The reversal of multidrug resistance in cancer (review). Anticancer Res., 13, 959 - 961.
15. KIKUCHI A, HOLAN V AND MINOWADA J. (1992). Effects of tumor necrosis factor alpha, interferon alpha and interferon gamma on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation. Cancer Immunol. Immunother., 35, 257 - 263.
16. KROEMER G, DE ALBORAN IM, GONZALO JA AND MARTINEZ-A C. (1993). Immunoregulation by cytokines. Crit. Rev. Immunol., 13, 163 - 191.
17. LAI G-M, CHEN Y-N. MICKLEY LA, FOJO AT AND BATES SE. (1991). P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int. J. Cancer, 49, 696 - 703.
18. LEONCE S, PIERRE A, ANSTETT M, PEREZ V, GENTON A, BIZZARI J-P AND ATASSI G. (1992). Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem. Pharmacol., 44, 1707 - 1715.
19. LUM BL, GOSLAND MP, KAUBISCH S AND SIKIC BI. (1993). Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy, 13, 88 - 109.
20. MCLEOD HL. (1994). Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? Eur. J. Cancer, 30A, 2039 2041.
21. MIZOGUCHI T, YAMADA F, FURUKAWA T, HIDAKA K, HISATSUGU T, SHIMAZU H, TSURUO T, SUMIZAWA T AND AKIYAMA S. (1990). Expression of the MDR1 gene in human gastric and colorectal carcinomas. J. Natl Cancer Inst., 82, 1679 - 1683.
22. MONTI E, MIMNAUGH EG AND SINHA BK. (1993). Synergistic antiproliferative effects of interleukin-1alpha and doxorubicin against the human ovarian carcinoma cell line (NIH-OVCAR-3). Biochem. Pharmacol., 45, 2099 - 2107.
23. NOONAN KF, BECK C, HOLYMAYER TA, CHIN JE, WUNDER JS, ANDRULIS IL, GAZDAR AF, WILLMAN CL, GRIFFITH B, VONHOFF DD AND RONINSON IB. (1990). Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl Acad. Sci. USA, 87, 7160 - 7164.
24. NOOTER K AND HERWEIJER H. (1991). Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer, 63, 663 - 669.
25. PARK J-G, KRAMER BS, LAI S-L, GOLDSTEIN LJ AND GAZDAR AF. (1990). Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J. Natl Cancer Inst., 82, 193 - 198.
26. RADERER M AND SCHEITHAUER W. (1993). Clinical trials of agents that reverse multidrug resistance. Cancer, 72, 3553 - 3563.
27. ROEPE PD. (1995). The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim. Biophys. Acta, 1241, 385 - 405.
28. RONINSON IB. (1991). Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press: New York.
29. SALMON SE, SOEHNLEN B, DALTON S, MELTZER P AND SCUDERI P. (1989). Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood, 74, 1723 - 1727.
30. SCALA S, PACELLI R, IAFFAIOLI RV, NORMANNO N, PEPE S, FRASCI G, GENUA G, TSURUO T, TAGLIAFERRI P AND BIANCO AR. (1991). Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res., 51, 4898 - 4902.
31. SCUDIERO DA, SHOEMAKER RH, PAULL KD, MONKS A, TIERNEY S, NOFZIGER TH, CURRENS MJ, SENIFF D, BOYD MR. (1988). Evaluation of a soluble tetrazolium/formazam assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48, 4827 - 4833.
32. SIDHU R AND BOLLON AP. (1993). Tumor necrosis factor activities and cancer therapy - a perspective. Pharmac. Ther., 57, 79 - 128.
33. VALENTI M, CIMOLI, G, PARODI S, MARIANI GL, VENTURINI M, CONTE PF AND RUSSO P. (1993). Potentiation of tumor necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur. J. Cancer, 29A, 1157 - 1161.
34. VALVERDE MA, DIAZ M, SEPULVEDA FV, GILL DR, HYDE SC AND HIGGINS CF. (1992). Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature, 355, 830 - 833.
35. WADKINS RM AND HOUGHTON PJ. (1993). The role of the drug-lipid interactions in the biological activity of modulators of multidrug resistance. Biochim. Biophys. Acta, 1153, 225 - 236.
36. WADLER S AND SCHWARTZ EL. (1990). Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50, 3473 - 3486.
37. WALTHER W AND STEIN U. (1994). Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J. Cancer Res. Clin. Oncol., 120, 471 - 478.
38. WALTHER W, STEIN U AND EDER C. (1994). RNA analysis using miniprep RNA in RT-PCR. Bio Techniques, 17, 674 - 675.
39. WU L, SMYTHE AM, STINSON SF, MULLENDORE LA, MONKS A, SCUDIERO DA, PAULL KD, KOUTSOUKOS AD, RUBINSTEIN LV, BOYD MR AND SHOMEAKER RH. (1992). Multidrug resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res., 52, 3029 - 3034.